A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations

NCT07646821 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Ropeginterferon
Alfa-2b
Azacitidine
MDS/AML

Interventions

DRUG: ropeginterferon alfa- 2b
DRUG: Azacitidine (AZA)

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]